Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 115

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study

Genovese, Mark C, Gaylis, Norman B, Sikes, David, Kivitz, Alan, Lewis Horowitz, Diane, Peterfy, Charles, Glass, Emmett V, Levine, Yaakov A, Chernoff, David · 2020 · The Lancet Rheumatology

Abstract

Background The inflammatory reflex plays a role in regulating innate and adaptive immunity by modulating cellular and molecular inflammatory pathways. The vagus nerve is a major constituent of the inflammatory reflex and studies have shown that the reflex can be activated by electrical stimulation of the vagus nerve. In this first in-human pilot study, we assessed the safety and efficacy of a novel miniaturised vagus nerve stimulation (VNS) device for the treatment of multidrug-refractory rheumatoid arthritis. METHODS Participants with moderately to severely active rheumatoid arthritis and prior insufficient response to two or more biological disease-modifying anti-rheumatic drugs or Janus kinase inhibitors with at least two different modes of action were enrolled in a two-stage study done at five clinical research sites in the USA. Stage 1 was open label; participants were implanted with a miniaturised VNS device, which was activated for 1 min once a day. In stage 2, participants were randomly assigned (1:1:1) to receive active stimulation (1 min once a day or 1 min four times a day) or sham stimulation (device implanted but not activated), with the sites and participants masked to treatment assignment. The primary outcome was incidence of treatment-emergent adverse events. Clinical efficacy was assessed as a key secondary outcome. The study was registered with ClinicalTrials.gov, NCT03437473. FINDINGS 14 patients were enrolled between March 13 and Aug 8, 2018. Three patients received stimulation in stage 1 and, following safety review board approval, the remaining 11 patients were implanted during stage 2 and randomly assigned to receive 1 min of stimulation once daily (n=3), 1 min of stimulation four times daily (n=4), or no stimulation (n=4) for 12 weeks. There were no device-related or treatment-related serious adverse events. Surgery-related adverse events were Horner's syndrome and vocal cord paralysis (in one patient each), which resolved without clinically significant sequelae. No deaths were recorded. INTERPRETATION VNS with a miniaturised neurostimulator was safe and well tolerated and reduced signs and symptoms of rheumatoid arthritis in patients with multidrug-refractory disease. These results support further evaluation in a larger randomised sham-controlled study. FUNDING SetPoint Medical.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2665-9913(20)30172-7

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 32

  1. Smolen, 2018, Rheumatoid arthritis, Nat Rev Dis Primers, 4, 10.1038/nrdp.2018.1 · DOI · Paper page
  2. Radawski, 2019, Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA, Rheumatol Ther, 6, 461, 10.1007/s40744-019-00168-5 · DOI
  3. Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202 · DOI · Paper page
  4. Keystone, 2004, Arthritis Rheum, 50, 1400, 10.1002/art.20217 · DOI · Paper page
  5. Smolen, 2009, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial, Lancet, 374, 210, 10.1016/S0140-6736(09)60506-7 · DOI · Paper page
  6. Kalden, 2017, Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment, Nat Rev Rheumatol, 13, 707, 10.1038/nrrheum.2017.187 · DOI · Paper page
  7. Listing, 2006, Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low—results from RABBIT, the German biologics register, Arthritis Res Ther, 8, R66, 10.1186/ar1933 · DOI · Paper page
  8. Rendas-Baum, 2011, Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors, Arthritis Res Ther, 13, R25, 10.1186/ar3249 · DOI
  9. Rubbert-Roth, 2009, Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review, Arthritis Res Ther, 11, S1, 10.1186/ar2666 · DOI · Paper page
  10. Favalli, 2017, The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives, Autoimmun Rev, 16, 1185, 10.1016/j.autrev.2017.10.002 · DOI
  11. Genovese, 2016, Baricitinib in patients with refractory rheumatoid arthritis, N Engl J Med, 374, 1243, 10.1056/NEJMoa1507247 · DOI · Paper page
  12. Genovese, 2005, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition, N Engl J Med, 353, 1114, 10.1056/NEJMoa050524 · DOI · Paper page
  13. Andersson, 2012, Reflex principles of immunological homeostasis, Annu Rev Immunol, 30, 313, 10.1146/annurev-immunol-020711-075015 · DOI · Paper page
  14. Koopman, 2016, Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis, Proc Natl Acad Sci USA, 113, 8284, 10.1073/pnas.1605635113 · DOI · Paper page
  15. Aletaha, 2010, 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, 69, 1580, 10.1136/ard.2010.138461 · DOI · Paper page
  16. Levine, 2020, Harnessing the inflammatory reflex for the treatment of inflammation-mediated diseases, Cold Spring Harb Perspect Med, 10, 10.1101/cshperspect.a034330 · DOI
  17. Heck, 2002, Vagus nerve stimulation therapy, epilepsy, and device parameters: scientific basis and recommendations for use, Neurology, 59, S31
  18. Martin, 1977, The influence of the parasympathetic nervous system on atrioventricular conduction, Circ Res, 41, 593, 10.1161/01.RES.41.5.593 · DOI
  19. van der Heijde, 2012, Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial, J Rheumatol, 39, 326, 10.3899/jrheum.111171 · DOI
  20. Curtis, 2015, Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients, Arthritis Care Res (Hoboken), 67, 1345, 10.1002/acr.22606 · doi:10.1002/acr.22606
  21. Mueller, 2012, Intraindividual long-term stability and response corridors of cytokines in healthy volunteers detected by a standardized whole-blood culture system for bed-side application, BMC Med Res Methodol, 12, 112, 10.1186/1471-2288-12-112 · DOI
  22. Centola, 2013, Development of a multi-biomarker disease activity test for rheumatoid arthritis, PLoS One, 8, 10.1371/journal.pone.0060635 · DOI · Paper page
  23. McInnes, 2007, Cytokines in the pathogenesis of rheumatoid arthritis, Nat Rev Immunol, 7, 429, 10.1038/nri2094 · DOI · Paper page
  24. D'Haens, 2016, Clinical trial of the effects of vagus nerve stimulation in biologic-refractory Crohn's disease, United European Gastroenterol J, 4, A641
  25. Aalbers, 2015, Vagus nerve stimulation lead removal or replacement: surgical technique, institutional experience, and literature overview, Acta Neurochir (Wien), 157, 1917, 10.1007/s00701-015-2547-9 · DOI
  26. Kahlow, 2013, Complications of vagal nerve stimulation for drug-resistant epilepsy: a single center longitudinal study of 143 patients, Seizure, 22, 827, 10.1016/j.seizure.2013.06.011 · DOI
  27. Baker, 2016, Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis, Ann Rheum Dis, 75, 1114, 10.1136/annrheumdis-2014-206934 · doi:10.1136/annrheumdis-2014-206934
  28. Østergaard, 2017, The OMERACT rheumatoid arthritis magnetic resonance imaging (MRI) scoring system: updated recommendations by the OMERACT MRI in Arthritis Working Group, J Rheumatol, 44, 1706, 10.3899/jrheum.161433 · DOI · Paper page
  29. Peterfy, 2016, MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study, Ann Rheum Dis, 75, 170, 10.1136/annrheumdis-2014-206015 · doi:10.1136/annrheumdis-2014-206015
  30. Koopman, 2017, Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis, J Intern Med, 282, 64, 10.1111/joim.12626 · DOI
  31. Bucksot, 2020, Parametric characterization of the rat Hering-Breuer reflex evoked with implanted and non-invasive vagus nerve stimulation, Exp Neurol, 327, 10.1016/j.expneurol.2020.113220 · DOI
  32. Rendas-Baum, 2011, Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors, Arthritis Res Ther, 13, R25, 10.1186/ar3249 · DOI

Cited by

See all 115

Metadata

Authors
Genovese, M. C., Gaylis, N. B., Sikes, D., Kivitz, A., Lewis Horowitz, D., Peterfy, C., Glass, E. V., Levine, Y. A., & Chernoff, D.
Venue
The Lancet Rheumatology
Publisher
Elsevier BV
Published
2020-09
Volume
2
Issue
9
Pages
e527-e538
ISSN
2665-9913
Cited by
115
References
2
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. https://app.cochat.ai/papers/10.1016/s2665-9913(20)30172-7
The paper
Genovese, M. C., Gaylis, N. B., Sikes, D., Kivitz, A., Lewis Horowitz, D., Peterfy, C., Glass, E. V., Levine, Y. A., & Chernoff, D. (2020). Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. The Lancet Rheumatology. https://doi.org/10.1016/s2665-9913(20)30172-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.